Search
Supernus Pharmaceuticals Inc
SUPNAdd to Watchlist
43.390USD
-0.360-0.82%
Close 09-23 16:00（ET）
2.52BMarket Cap
LossP/E TTM
Supernus Pharmaceuticals Inc (SUPN) Revenue Performance
Updated: Jun 30, 2026Last year, Supernus Pharmaceuticals Inc generated 304.65M USD for its biggest-performing segment, Net product sales-Qelbree. The United States made the largest contribution, accounting for 718.95M USD last year. For the latest quarter, Supernus Pharmaceuticals Inc reported the revenue of 89.24M USD for the period ending 2026-06-30, which came from the top-performing segment, Net product sales-Qelbree. United States contributed the highest revenue, at 219.06M USD.
By Business
Revenue
Proportion
Annual
Annual
Quarterly
Net product sales-Qelbree
Net product sales - GOCOVRI
Collaboration revenue
Net product sales-APOKYN
Net product sales- Trokendi XR
Net product sales- Oxtellar XR
Royalty revenues
Other
ONAPGO
Net product sales-MYOBLOC
Net product sales-XADAGO
Net product sales - Osmolex ER
FY2025
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
Net product sales-Qelbree
304.65M(42.37%)
241.27M(36.46%)
140.19M(23.08%)
61.32M(9.19%)
9.88M(1.70%)
--(--)
--(--)
Net product sales - GOCOVRI
146.82M(20.42%)
130.82M(19.77%)
119.64M(19.69%)
104.42M(15.65%)
9.78M(1.69%)
--(--)
--(--)
Collaboration revenue
53.00M(7.37%)
--(--)
--(--)
--(--)
--(--)
--(--)
--(--)
Net product sales-APOKYN
47.77M(6.64%)
73.93M(11.17%)
75.08M(12.36%)
75.31M(11.29%)
99.23M(17.12%)
74.30M(14.28%)
--(--)
Net product sales- Trokendi XR
42.42M(5.90%)
63.20M(9.55%)
94.34M(15.53%)
261.22M(39.15%)
304.82M(52.58%)
319.64M(61.42%)
295.21M(75.16%)
Net product sales- Oxtellar XR
40.70M(5.66%)
99.46M(15.03%)
113.40M(18.67%)
115.34M(17.29%)
110.71M(19.09%)
98.72M(18.97%)
88.19M(22.45%)
Royalty revenues
39.42M(5.48%)
24.12M(3.64%)
33.59M(5.53%)
17.81M(2.67%)
12.27M(2.12%)
11.05M(2.12%)
9.36M(2.38%)
Other
26.91M(3.74%)
29.01M(4.38%)
31.28M(5.15%)
31.82M(4.77%)
--(--)
--(--)
--(--)
ONAPGO
17.25M(2.40%)
--(--)
--(--)
--(--)
--(--)
--(--)
--(--)
Net product sales-MYOBLOC
--(--)
--(--)
--(--)
--(--)
19.51M(3.37%)
9.75M(1.87%)
--(--)
Net product sales-XADAGO
--(--)
--(--)
--(--)
--(--)
13.39M(2.31%)
6.94M(1.33%)
--(--)
Net product sales - Osmolex ER
--(--)
--(--)
--(--)
--(--)
188.00K(0.03%)
--(--)
--(--)
By Region
Revenue
Proportion
Annual
Annual
Quarterly
United States
FY2025
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
United States
718.95M(100.00%)
661.82M(100.00%)
607.52M(100.00%)
667.24M(100.00%)
579.77M(100.00%)
520.40M(100.00%)
392.75M(100.00%)